Home » Topics » BioWorld Science

BioWorld Science
RSS

Discovery of a druggable target for traumatic brain injury

Aug. 20, 2018

TGF-beta inhibition restores regeneration in acute liver injury

Aug. 20, 2018

RXi Pharmaceuticals, Karolinska Institutet collaborate on sd-rxRNA for cancer immunotherapy

Aug. 17, 2018

Dose escalation cleared to continue in first-in-human MAGE-A4 SPEAR T-cell trial

Aug. 17, 2018

ADAM-17 inhibitor ZLDI-8 increases cancer sensitivity to chemotherapeutic drugs

Aug. 17, 2018

HitGen to collaborate with LG Chem on drug discovery using DNA-encoded libraries

Aug. 17, 2018

Lenvatinib approved in the U.S. for unresectable hepatocellular carcinoma

Aug. 17, 2018

TrovaGene completes second dosing cohort in phase Ib/II study of onvansertib in AML

Aug. 17, 2018

Fasinumab topline phase III data presented in patients with chronic pain from OA of the knee or hip

Aug. 17, 2018

Principia Biopharma patents proteasome subunit beta type-8/beta type-9 inhibitors

Aug. 17, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...